Elsevier

Life Sciences

Volume 39, Issue 6, 11 August 1986, Pages 549-555
Life Sciences

Peripheral-type benzodiazepine-binding sites in platelets of schizophrenics with and without tardive dyskinesia

https://doi.org/10.1016/0024-3205(86)90512-6Get rights and content

Abstract

The density of peripheral-type benzodiazepine (BZ)-binding sites was studied in platelets of 10 medicated chronic schizophrenics with tardive dyskinesia (TD), 10 medicated chronic schizophrenics without TD, 7 drug-free schizophrenics, and 10 normal controls. The age range of the study population was 36–60 years. Age and sex distribution were similar in all 4 groups. The unmedicated schizophrenics did not differ in their maximal binding capacity from the healthy controls. A significant decrease in the density of peripheral-type BZ-binding sites in platelets was observed in treated schizophrenics both with and without TD in comparison to controls and untreated schizophrenics. The reduction in [3H]PK 11195 binding was more pronounced in TD patients (31.3% of controls) than in patients without TD (21.1% of controls). However, this parameter failed to discriminate statistically between TD and non-TD medicated schizophrenics.

References (33)

  • J.L. Waddington

    Trends Neurosci.

    (1985)
  • T. Taniguchi et al.

    Biochem. Pharmac.

    (1982)
  • J. Benavides et al.

    Biochem. Pharmac.

    (1984)
  • H. Schoemaker et al.

    Eur. J. Pharmac.

    (1981)
  • M. Gavish et al.

    Eur. J. Pharmac.

    (1986)
  • M. Gavish et al.

    Eur. J. Pharmac.

    (1985)
  • M.S. Briley et al.

    Eur. J. Pharmac.

    (1982)
  • T.D. Reisine et al.

    Brain Res.

    (1979)
  • H. Schoemaker et al.

    Brain Res.

    (1982)
  • S.R.B. Weiss et al.

    Life Sci.

    (1985)
  • S. Pellow et al.

    Life Sci.

    (1984)
  • C.G. Goetz et al.

    Clin. Neuropharmac.

    (1982)
  • G.E. Crane

    Br. J. Psychiat.

    (1973)
  • H.L. Klawans

    Am. J. Psychiat.

    (1973)
  • S.H. Snyder

    Science

    (1984)
  • M.A. Richardson et al.

    Am. J. Psychiat.

    (1982)
  • Cited by (26)

    • TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward

      2019, Pharmacology and Therapeutics
      Citation Excerpt :

      These studies may provide important information that may help the interpretation of current TSPO-PET findings. As far back as 1986, there were studies examining the levels of TSPO in platelets from schizophrenia subjects (Gavish et al., 1986; Weizman et al., 1986). Two different studies showed that the maximal number of [3H]PK11195 binding sites (Bmax) in platelets from untreated schizophrenia subjects did not differ from age-matched healthy controls.

    View all citing articles on Scopus
    View full text